# A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

> **NCT06565650** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Bausch & Lomb Incorporated** · enrollment: 216 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** Miebo
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT06565650
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06565650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06565650, "A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06565650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*